Advances in psychiatric research, spanning the entire spectrum of biological, psychological, and social aspects of mental processes and functions, have transformed the field of psychiatry. More in this inaugural piece by Psychiatric Times' Editor in Chief.
In his blog for Mental Illness Awareness Week, NIMH Director Thomas Insel talks about the complexity of mental disorders and the need for scientists, clinicians, patients, and families to work together in searching for better treatment.
The discovery that a single IV infusion of low-dose (subanesthetic) ketamine exerts rapid antidepressant effects constitutes an expansion in our understanding of the neurobiology of depression and provides new avenues for drug development.
The SSRIs, although principally targeting serotonin transporter, are complex drugs that might work on other neurotransmitter and receptor systems. It is likely worthwhile to look at the effects of other monoamine and neuropeptide systems on the enzymatic machinery cleaving the amyloid precursor protein.
What is your first impression of this image and why?
Some doubt that even $650 million will go very far in speeding up the solution to the vast jigsaw puzzle known as neuroscience. According to this author, we have learned a great deal in basic science, but nothing at all that translates to better clinical care.
When psychosocial treatments are delivered with high quality and fidelity, outcomes improve. That is the parity all of us should be fighting for. More in this commentary by NIMH Director Thomas Insel, MD.
In the trenches of Alzheimer research, the battle continues . . . but where do we stand? Is the war on AD dementia nearing conclusion, or are we simply in the initial throes of the fight? Three experts weigh in.
A discussion of computerized cognitive training programs with the most independent supportive research that demonstrates a previously unrecognized degree of neuroplasticity, or cognitive flexibility, in the brain.
We talk about mental disorders as brain disorders, but what does that really mean? How does it change the way we think about autism, schizophrenia, depression, bipolar, and other illnesses? The answer to these questions are still evolving. More in this video exclusive with NIMH Director Thomas Insel, MD.